ANXV / Annexin - LARVOL DELTA

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (clinicaltrials.gov) - P2 | N=16 | Completed | Sponsor: Annexin Pharmaceuticals AB | Active, not recruiting ➔ Completed

Trial completion • Retinal Vein Occlusion • ANXA5

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (clinicaltrials.gov) - P2 | N=16 | Active, not recruiting | Sponsor: Annexin Pharmaceuticals AB | Trial completion date: Jul 2024 ➔ Nov 2024

Trial completion date • Retinal Vein Occlusion • ANXA5

New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology. (PubMed, Pharmaceuticals (Basel)) - "This review explores the current understanding of the potential roles of PS as a target and Annexin A5 as a therapeutic. The clinical development status of Annexin A5 as a therapeutic and the potential utility of PS-Annexin A5 as a theranostic pairing in retinal vascular conditions in particular is described."

Journal • Review • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration • ANXA5

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (clinicaltrials.gov) - P2 | N=16 | Active, not recruiting | Sponsor: Annexin Pharmaceuticals AB | Recruiting ➔ Active, not recruiting

Enrollment closed • Retinal Vein Occlusion • ANXA5

Study update of a Phase 2a/Proof of concept study with ANXV in patients with RVO. (ARVO 2024) - "Based on a limited number of patients, safety and tolerability of 2 and 4 mg ANXV i.v. for 5 days appears acceptable. Improvements have been reported before anti-VEGF treatment and an atypical low requirement of anti-VEGF for up to 12 months post-ANXV have been observed. Safety and effect signal data support a continuation of the study."

Clinical • P2a data • Ophthalmology • Retinal Vein Occlusion • ANXA5

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (clinicaltrials.gov) - P2 | N=22 | Recruiting | Sponsor: Annexin Pharmaceuticals AB | Trial completion date: Nov 2023 ➔ Jun 2024 | Trial primary completion date: Oct 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Retinal Vein Occlusion • ANXA5

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (clinicaltrials.gov) - P2 | N=28 | Recruiting | Sponsor: Annexin Pharmaceuticals AB | Trial completion date: Aug 2023 ➔ Nov 2023 | Trial primary completion date: Jun 2023 ➔ Oct 2023

Trial completion date • Trial primary completion date • Retinal Vein Occlusion

ANXV (a human recombinant Annexin A5) is well-tolerated and safe in Phase 1 First In Human clinical trial and is currently in Phase 2 in Retinal Vein Occlusion. (ARVO 2023) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • P1 data • P2 data • Macular Edema • Ophthalmology • Retinal Vein Occlusion • ANXA5

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (clinicaltrials.gov) - P2 | N=28 | Recruiting | Sponsor: Annexin Pharmaceuticals AB | Trial completion date: Mar 2023 ➔ Aug 2023 | Trial primary completion date: Feb 2023 ➔ Jun 2023

Trial completion date • Trial primary completion date • Retinal Vein Occlusion

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (clinicaltrials.gov) - P2 | N=28 | Recruiting | Sponsor: Annexin Pharmaceuticals AB | Not yet recruiting ➔ Recruiting

Enrollment open • Retinal Vein Occlusion

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (clinicaltrials.gov) - P2 | N=28 | Not yet recruiting | Sponsor: Annexin Pharmaceuticals AB

New P2 trial • Retinal Vein Occlusion

First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: Annexin Pharmaceuticals AB | Recruiting ➔ Completed

Trial completion

The CO-ANNEXIN study; assessing the efficacy and safety of ANXV (recombinant Annexin A5) in moderate tosevere COVID-19. De CO-ANNEXIN studie; onderzoek naar de effectiviteit en veiligheid van ANXV (recombinant Annexine A5) inmatig tot ernstige COVID-19. (clinicaltrialsregister.eu) - P2; N=12; Ongoing; Sponsor: MUMC AZm

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • IL10 • IL18

First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers (clinicaltrials.gov) - P1; N=46; Recruiting; Sponsor: Annexin Pharmaceuticals AB

New P1 trial

Serum biomarker analysis at the protein level on pulmonary hypertension secondary to old anterior myocardial infarction. (PubMed, Pulm Circ) - "Receiver operating characteristic curve analysis revealed haptoglobin (cut-off value: 78.295, sensitivity: 62.8%, specificity: 94.4%), annexin A5 (cut-off value: 151.925, sensitivity: 41.9%, specificity: 82.4%), and Ig mu chain C region (cut-off value: 168.885, sensitivity: 86.0%, specificity: 79.6%) (P<0.01). Three circulating serum proteins can be useful for the categorization of OAMI patients with and without PH."

Biomarker • Journal • Cardiovascular • Fibrosis • Hypertension • Myocardial Infarction • Pulmonary Arterial Hypertension • Respiratory Diseases • HP

An interaction of heart disease-associated proteins POPDC1/2 with XIRP1 in transverse tubules and intercalated discs. (PubMed, BMC Mol Cell Biol) - "Mutations in human POPDC1, POPDC2 and in human XIRP1, all cause pathological cardiac arrhythmias, suggesting a possible role for POPDC1/2 and XIRP1 interaction in normal cardiac conduction."

Journal • Atrial Fibrillation • Cardiovascular • Heart Failure

Proteomic Analysis of Porcine-Derived Collagen Membrane and Matrix. (PubMed, Materials (Basel)) - "The structural proteins vimentin, actin-based microfilaments (ACTB), annexins (ANXA1, ANXA5), tubulins (TUBA1B, TUBB), and histones (H2A, H2B, H4) were also identified. Examples of membrane-only proteins are COL12A1 and COL14A1, and, of matrix only proteins, elastin (ELN). The proteomic signature thus revealed the similarities between but also some individual proteins of collagen membrane and matrix."

Journal • ANXA1 • COL1A1 • COL1A2 • Collagen Type IV • VIM

Interplay between reactive oxygen species and autophagy in the course of age-related macular degeneration. (PubMed, EXCLI J) - "Vascular dysfunction and hypoxia, as well as circulating autoantibodies against autophagy regulators (anti-S100A9, anti-ANXA5, and anti-HSPA8, A9 and B4) compromise an autophagy-mediated mechanism as well. Metformin, the autophagic stimulator, may act as a senostatic drug to inhibit the senescent phenotype in the age-related macular degeneration. PGC-1α , Sirt1 and AMPK represent new therapeutic targets for interventions in this disease."

Journal • Review • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Immunology • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • AMPK • S100A9 • SIRT1

Proteomic identification of early urinary-biomarkers of acute kidney injury in preterm infants. (PubMed, Sci Rep) - "Finally, enzyme-linked immunosorbent assays revealed that the levels of annexin A5, neutrophil gelatinase-associated lipocalin (NGAL), and protein S100-P were significantly higher in the samples of the first urine from patients with AKI than in those from patients without AKI. In conclusion, urinary annexin A5, NGAL and protein S100-P levels are promising biomarkers for early, accurate prediction of AKI in preterm infants."

Biomarker • Journal • Acute Kidney Injury • Nephrology • Renal Disease

Analysis of Gene Expression of Pseudoarthrosis Tissue in Congenital Short Femur, Initial Study and First Exprerience. (PubMed, Acta Chir Orthop Traumatol Cech) - "Some genes were considered over-expressed in PFFD tissue compared with the control sample (e.g. the gene for calcitonin receptor, collagen XII, I alpha 2, collagen II, IX, FGFR2, fibronectin, integrin) and other genes under-expressed (e.g. the gene for annexin A5, collagen XVIII alpha1, collagen I alpha1, cathepsin K, FGFR1, FGFR3, IGF2, VEGFB)...So far, the results cannot be generalized; this is the first step for follow-up experiments to confirm the suggested information and to integrate it with clinical findings, such as the alternative blood supply of affected extremity in some patients. Key words: proximal femoral focal deficiency, gene expression, microarray analysis, angiogenesis, osteogenesis."

Journal • Osteoarthritis

Targeted tumor coating with antigenic, CTL-recognizable peptides via Annexin A5 chimeric constructs following chemotherapy redirects adaptive CD8+ T cell immunity for tumor clearance. (PubMed, Cell Mol Immunol) - No abstract available

Journal • Oncology

Anionic Phospholipid Expression as a Molecular Target in Listeria monocytogenes and Escherichia coli. (PubMed, Int J Antimicrob Agents) - "As measured by the IC50, conjugation to ANXA5 resulted in increasing the antibiotic activity of ampicillin against L. monocytogenes and E. coli by more than 4 and 3 orders of magnitude, respectively, compared to free ampicillin, while activity of moxifloxacin against L. monocytogenes is increased by 4 orders of magnitude. Given the conservation of anionic phospholipid expression in pathologies such as oncogenesis, and other bacterial/viral/parasitic infections, we hypothesize that a therapeutic modality targeting anionic phospholipid expression may be a viable chemotherapeutic strategy in many infectious diseases."

Journal • Infectious Disease • Oncology

Inclusion of African American/black adults in a pilot brain proteomics study of Alzheimer's disease. (PubMed, Neurobiol Dis) - "These proteins were consistent with the literature and included glial fibrillary acidic protein, peroxiredoxin-1, and annexin A5...These differences generally were reflective of differential expression of proteins in AD that occurred in only a single racial/ethnic group. Overall, this pilot study suggests that disease understanding can be furthered by including diversity in racial/ethnic groups; however, this must be done on a larger scale."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • GFAP

Chemical Proteomic Profiling of Lysophosphatidic Acid-binding Proteins. (PubMed, Anal Chem) - "Moreover, we validated that two of these proteins, annexin A5 and phosphoglycerate kinase 1, can bind directly with LPA. Together, we developed a novel LPA probe for the identification and characterizations of LPA-binding proteins from the entire human proteome. The method should be adaptable for the identification of other lipid-binding proteins."

Journal • Oncology

Calcium relieves fluoride-induced bone damage through the PI3K/AKT pathway. (PubMed, Food Funct) - "It also decreased the expression of AnnexinA5 (Anxa5), 3'-phosphoinositide-dependent kinase 1 (PDK1) and B-cell lymphoma-2 (Bcl-2) (p < 0.05, p < 0.01), which finally activated the PI3K/AKT pathway. On the other hand, CaCO3 supplementation reversed the histopathological injury along with the levels of ALP, StrACP and serum Ca, alleviating the gene expression levels of PI3K/AKT pathway-related markers. Altogether, we can conclude that CaCO3 supplementation mitigated F-induced bone damage via the PI3K/AKT signaling pathway."

IO Biomarker • Journal • Hematological Malignancies • Oncology